Conclusion
Our study demonstrated, in laCSCC and reCSCC, 50% of patients with
parotid metastasis with 32.4% extracapsular parotid metastasis spread;
13.5% overall rate of neck occult metastasis, 51.3% clinical neck
metastasis with 37.8% neck extracapsular spread. The risk of positive
parotid metastasis evolving into positive neck metastasis was 37.6. The
clinical skin T4 tumor and presence of parotid metastasis negatively
impacted patient survival; P1 stage resulted in 30% and 5% survival at
5 years and 10 years, respectively. Our outcomes support the surgically
aggressive approach for laCSCC and reCSCC, with partial parotidectomy
for P0 and total parotidectomy for P1-3 stages and selective neck
dissection I-III in all patients.